Tirzepatide Produces Significant Weight Loss in Adults With Type 1 Diabetes and Obesity
In the first RCT of tirzepatide in type 1 diabetes, participants lost an average of 10.3 kg (8.8%) over 12 weeks while also reducing insulin needs by 35% with no serious adverse events.
Quick Facts
What This Study Found
Over 12 weeks, tirzepatide produced a mean weight loss of 10.3 kg versus 0.7 kg with placebo (treatment difference: -8.7 kg, p<0.0001), representing 8.8% body weight reduction. Every participant (100%) on tirzepatide achieved at least 5% weight loss, and 45% achieved at least 10% loss, compared to 9% and 0% on placebo.
Tirzepatide also improved HbA1c by -0.4% versus placebo (p=0.05) and reduced total daily insulin dose by 24.2 units/day (35.1% reduction vs placebo, p=0.0002). No significant adverse events occurred in either group. Twenty-two of 24 participants completed the study.
Key Numbers
How They Did This
This was a 12-week, phase 2, double-blind, placebo-controlled trial in adults with type 1 diabetes and BMI >30 kg/m². Participants were randomized to weekly subcutaneous tirzepatide (2.5 mg for 4 weeks, then 5.0 mg for 8 weeks) or placebo. The primary endpoint was change in body weight at 12 weeks. Secondary endpoints included HbA1c, insulin dose, and safety.
Why This Research Matters
Obesity affects a growing proportion of people with type 1 diabetes and increases cardiovascular risk, but no weight loss medications have been specifically studied or approved for this population. This first-ever RCT of tirzepatide in type 1 diabetes shows it can produce substantial weight loss and reduce insulin needs without safety concerns — potentially opening a new treatment avenue for millions of patients.
The Bigger Picture
Tirzepatide and other GLP-1-based peptide drugs have transformed type 2 diabetes and obesity treatment, but type 1 diabetes has been overlooked. This trial bridges that gap, showing the dual GIP/GLP-1 agonist is effective and safe even when patients depend entirely on exogenous insulin. With obesity rates rising among type 1 diabetes patients, this could lead to the first approved weight management therapy specifically studied in this population.
What This Study Doesn't Tell Us
This was a small phase 2 trial with only 24 participants and 12-week duration. The tirzepatide dose was capped at 5 mg (lower than the 10-15 mg used in type 2 diabetes obesity studies), so the full potential may not have been captured. Longer-term safety, durability of weight loss, and effects at higher doses need evaluation. The study excluded participants with BMI under 30, so applicability to overweight (non-obese) type 1 diabetes patients is unknown.
Questions This Raises
- ?Would higher tirzepatide doses (10-15 mg) produce even greater weight loss in type 1 diabetes, and would they remain safe?
- ?Is the weight maintained after stopping tirzepatide, or does it return as seen in type 2 diabetes studies?
- ?Could the 35% insulin dose reduction translate to reduced hypoglycemia risk in longer-term treatment?
Trust & Context
- Key Stat:
- 100% achieved ≥5% weight loss Every single participant on tirzepatide lost at least 5% of their body weight in just 12 weeks, with nearly half losing 10% or more — while also reducing their insulin needs by over a third.
- Evidence Grade:
- This is a phase 2, double-blind, placebo-controlled randomized trial — a strong study design. However, the small sample size (n=24) and short duration (12 weeks) mean these are preliminary results that require confirmation in larger, longer phase 3 trials.
- Study Age:
- Published in 2026, this is the first randomized controlled trial of tirzepatide in type 1 diabetes, making it a landmark study that could shift clinical practice if confirmed in larger trials.
- Original Title:
- Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.
- Published In:
- Diabetes care, 49(1), 161-170 (2026)
- Authors:
- Snaith, Jennifer R(3), Frampton, Ruth(2), Samocha-Bonet, Dorit, Greenfield, Jerry R
- Database ID:
- RPEP-16147
Evidence Hierarchy
Frequently Asked Questions
Why haven't weight loss drugs been studied in type 1 diabetes before?
Type 1 diabetes involves complete insulin dependence, which adds complexity to weight management studies — researchers must monitor for dangerous blood sugar swings when adding new medications. Most incretin drug trials excluded type 1 patients. This trial is significant because it specifically designed safety monitoring for insulin-dependent patients and found tirzepatide was safe.
Could tirzepatide replace insulin in type 1 diabetes?
No — people with type 1 diabetes cannot produce their own insulin and will always need it. However, tirzepatide reduced total daily insulin doses by 35%, which lightens the treatment burden and may improve blood sugar stability. It's being studied as an add-on therapy, not a replacement for insulin.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-16147APA
Snaith, Jennifer R; Frampton, Ruth; Samocha-Bonet, Dorit; Greenfield, Jerry R. (2026). Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.. Diabetes care, 49(1), 161-170. https://doi.org/10.2337/dc25-2379
MLA
Snaith, Jennifer R, et al. "Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.." Diabetes care, 2026. https://doi.org/10.2337/dc25-2379
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Random..." RPEP-16147. Retrieved from https://rethinkpeptides.com/research/snaith-2026-tirzepatide-in-adults-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.